Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Holding NBIX?
Track your performance easily
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$107.84 - $157.98
Previous Close$127.01
Volume807.40K
Average Volume (3M)972.68K
Market Cap
$12.86B
Enterprise Value$11.88B
Total Cash (Recent Filing)$1.23B
Total Debt (Recent Filing)$251.40M
Price to Earnings (P/E)34.0
Beta0.49
Next Earnings
Feb 11, 2025EPS Estimate
$1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding101,246,911
10 Day Avg. Volume1,193,008
30 Day Avg. Volume972,684
Standard Deviation0.08
R-Squared0.05
Alpha0.00245
Financial Highlights & Ratios
Price to Book (P/B)4.73
Price to Sales (P/S)5.74
Price to Cash Flow (P/CF)20.40
P/FCF Ratio21.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.30
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda21.35
Forecast
1Y Price Target
$166.47Price Target Upside32.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement raised its 2024 sales outlook for Ingrezza again, which is viewed as a sign of continued solid execution on the product.
Market Position And InnovationNeurocrine's decision to continue with the trial for NBI-1117568 is supported by data, indicating that the drug's mechanism of action allows for differentiation potential despite investor concerns about lack of dose response.
Strategic Growth And OpportunitiesThe outlook for crinicerfont's upcoming PDUFA and launch was a key topic, indicating potential new opportunities for the company.
Bears Say
Clinical TrialsThe assumed probability of success for NBI-568 at these levels seems miniscule, and today’s development won’t help on that front.
EarningsGAAP EPS of $1.24 was approximately 18% below the consensus of $1.52, reflecting a shortfall in earnings.
Product LaunchManagement expects payor coverage will likely be limiting to early uptake of crinecerfont given commercial payors typically have new-to-market coverage restrictions.
---
Ownership Overview
1.04% Insiders
23.40% Mutual Funds
9.23% Other Institutional Investors
37.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $107.84 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Feb 11, 2025 which is in 89 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Oct 30, 2024. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.517 by -$0.277.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.61.
How many shares outstanding does Neurocrine have?
Neurocrine has 101,246,910 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.24 in its last earnings report, missing expectations of $1.517. Following the earnings report the stock price went up 7.006%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 176M.
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$166.47 (32.63% Upside)
$166.47 (32.63% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 74.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.51%
12-Months-Change
Fundamentals
Return on Equity
16.35%
Trailing 12-Months
Asset Growth
24.11%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q3 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$166.47
▲(32.63% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
16/24 ratings generated profit
1 Year Average Return
+8.88%
reiterated a buy rating 16 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.88% per trade.
---